Novavax Inc (NASDAQ: NVAX) delayed ramping up COVID-19 vaccine production again on Monday and said it was unlikely to seek regulatory approval for its shot in Europe, UK, and the United States until Q3 of 2021. Shares of the company slid about 7% in premarket trading on Tuesday. Following the ...

https://invezz.com/news/2021/05/11/heres-why-novavax-stock-fell-again-on-tuesday-morning/

#InvezzNews